A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Inclusion Criteria:

- Be at least 18 years of age.

- Provided written informed consent.

- Have a reported history of dry eye Have a history of use or desire to use eye drops
for dry eye

Exclusion Criteria:

- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit
1.

- Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or
conjunctiva, within the last 12 months.

- Have any planned ocular and/or lid surgeries over the study period.

- Have corrected visual acuity greater than or equal to +0.7 as assessed by Early
Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit .

- Have an uncontrolled systemic disease.

- Be a woman who is pregnant, nursing or planning a pregnancy.

- Be a woman of childbearing potential who is not using an acceptable means of birth
control

- Have a known allergy and/or sensitivity to the test article or its components.

- Have a condition or be in a situation which the investigator feels may put the
subject at significant risk, may confound the study results, or may interfere
significantly with the subject's participation in the study

- Be currently enrolled in an investigational drug or device study or have used an
investigational drug or device within 45 days of Visit 1 Be unable or unwilling to
follow instructions, including participation in all study assessments and visits